866-997-4948(US-Canada Toll Free)

Gemzar (Non Small Cell Lung Cancer) Analysis and Forecasts to 2015

Published By :

GlobalData

Published Date : Oct 2011

Category :

Non Small Cell Lung Cancer

No. of Pages : 33 Pages

 

GlobalDatas pharmaceuticals report, Gemzar (Non Small Cell Lung Cancer) - Analysis and Forecasts to 2015 provides Gemzar sales forecasts for the US, EU5 and Japan. In addition, it covers detailed clinical assessment of the drug, factors impacting drug sales, competitive landscape, and analysis of sales performance during the forecast period (2002- 2015). The report also includes information on Non Small Cell Lung Cancer market. This report is built using data and information sourced from GlobalDatas proprietary databases, primary and secondary research using Companys corporate website, SEC filings, investor presentations and featured press releases, both from company and industry-specific third party sources, put together with in-house analysis, by GlobalData\'s team of industry experts.

 

Note: This is a on-demand report and will be delivered within 7 business days (excluding weekends) of the purchase.

 

Scope

  • Therapy area profile including patient population for the US, EU5 and Japan (seven major markets)
  • Analysis and review of Gemzar including sales data 
  • Qualitative and quantitative assessment of market space
  • Analysis of the trends, drivers and restraints shaping and defining the markets
  • In-depth analysis of Gemzar including efficacy, safety, pricing, competition and other details which influence its sales potential
  • Detailed sales forecasts for 2002-2015 for Gemzar in the US, EU5 and Japan

Reasons to buy

  • Understand and capitalize by identifying products that are most likely to ensure a robust return
  • Stay ahead of competition by understanding the changing competitive landscape
  • Effectively plan your M&A and partnership strategies by identifying drugs with the most promising sales potential
  • Make more informed business decisions from insightful and in-depth analysis of the drugs performance 
  • Examine the historical sales performance of a drug in seven major markets
  • Obtain sales forecast for currently marketed/pipeline drug for 2011-2020 for all seven major markets

Table of Contents

 

1 Table of contents 2
1.1 List of Tables 3
1.2 List of Figures 3


2 Introduction 4
2.1 NSCLC Market 4
2.2 Epidemiology 4
2.3 Etiology 6
2.3.1 Tobacco 6
2.3.2 Radon 6
2.3.3 Asbestos 6
2.3.4 Other Environmental Agents 7
2.4 GlobalData Report Guidance 8


3 NSCLC Disease: Market Characterization 9
3.1 NSCLC Disease Market 9
3.2 NSCLC Disease Market Forecasts and CAGR 9
3.3 Drivers for the NSCLC Disease Market 9
3.3.1 High Incidence 10
3.3.2 High Mortality Rate 11
3.3.3 Increased Use of Chemotherapy in Early Stages of NSCLC 11
3.3.4 Emergence of Targeted Drugs and Maintenance Therapy 11
3.3.5 Promising Pipeline Drugs 11


4 Tumor-Node-Metastases (TNM) Classification of NSCLC 12


5 Gemzar 15
5.1 Introduction 15
5.2 Mechanism of Action 15
5.3 Clinical Studies 15
5.4 Approval History of Gemzar 16
5.5 Factors Affecting Sales of Gemzar 16
5.5.1 Generic Erosion 16
5.5.2 Low Efficacy 16
5.5.3 Average Toxicity 16
5.5.4 Low Annual Cost of Treatment 16
5.5.5 Patent Expiration and Increasing Competition 16
5.6 Drug Risk Benefit Score 17
5.6.1 Efficacy 17
5.6.2 Safety 17
5.6.3 Compliance 17
5.6.4 Dosing Convenience 17
5.7 Intensity of Competition 17
5.8 Sales forecast 18
5.8.1 Target Patient Pool of Gemzar 18
5.8.2 Dosing 19
5.8.3 Market Penetration 19
5.8.4 Annual Cost of Therapy 19
5.8.5 Sales Projections of Gemzar 20


6 NSCLC Market: Appendix 29
6.1 Market Definitions 29
6.2 List of Abberiviations 29
6.3 Research Methodology 29
6.3.1 Coverage 30
6.3.2 Secondary Research 30
6.3.3 Forecasting 30
6.3.4 Number of Patients Approved to take the Drug 30
6.3.5 Net Penetration of Drug 31
6.3.6 Net Annual Dosing 32
6.3.7 Annual Cost of Therapy 32
6.3.8 Primary Research 32
6.3.9 Expert Panels 32
6.4 Contact Us 33
6.5 Disclaimer 33
6.6 Sources 33

List of Table


Table 1: NSCLC, Incidences and Mortality, 20082030 5
Table 2: NSCLC, Global, Market Size Forecast ($bn), 20092020 9
Table 3: Clinical Trial Results (first-line treatment) 15
Table 4: Approval History of Gemzar 16
Table 5: Drug Risk Benefit Score of Gemzar 17
Table 6: Annual Cost of Therapy of Gemzar as Monotherapy 19
Table 7: Annual Cost of Therapy of Gemzar in Combination Therapy 20
Table 8: Average Annual Cost of Therapy of Gemzar 20
Table 9: Gemzar, NSCLC, Global Sales Forecast ($m), 2002-2015 21
Table 10: Gemzar, NSCLC, The US, Sales Forecast ($m), 2002-2015 22
Table 11: Gemzar, NSCLC, The UK, Sales Forecast ($m), 2002-2015 23
Table 12: Gemzar, NSCLC, France, Sales Forecast ($m), 2002-2015 24
Table 13: Gemzar, NSCLC, Germany, Sales Forecast ($m), 2002-2015 25
Table 14: Gemzar, NSCLC, Italy, Sales Forecast ($m), 2002-2015 26
Table 15: Gemzar, NSCLC, Spain, Sales Forecast ($m), 2002-2015 27
Table 16: Gemzar, NSCLC, Japan, Sales Forecast ($m), 2002-2015 28

List of Chart


Figure 1: Percentage Distribution of Top 20 Cancers 4
Figure 2: Difference of % Distribution of Incidence and Mortality of Top 20 Cancers 5
Figure 3: Percentage Distribution of Different Types of NSCLC according to Incidence, 2008 6
Figure 4: % Share of Risk Factors in Developed Countries 7
Figure 5: Per Capita Cigarette Consumption, The US, 1976-2006 7
Figure 6: NSCLC, Global, Market Size Forecast ($bn), 20092020 9
Figure 7: NSCLC, Global, Incidence (in millions), 2008-2030 10
Figure 8: Oncology, Global, Incidence (in millions), 2008-2030 10
Figure 9: Broad Classification of NSCLC 12
Figure 10: Detailed TNM Classification 13
Figure 11: Classification of NSCLC 14
Figure 12: Drug Model Diagram of Gemzar 18
Figure 13: Gemzar, NSCLC, Global Sales Forecast ($m), 2002-2015 21
Figure 14: Gemzar, NSCLC, Global Sales Distribution, (2010) 21
Figure 15: Gemzar, NSCLC, The US, Sales Forecast ($m), 2002-2015 22
Figure 16: Gemzar, NSCLC, The UK, Sales Forecast ($m), 2002-2015 23
Figure 17: Gemzar, NSCLC, France, Sales Forecast ($m), 2002-2015 24
Figure 18: Gemzar, NSCLC, Germany, Sales Forecast ($m), 2002-2015 25
Figure 19: Gemzar, NSCLC, Italy, Sales Forecast ($m), 2002-2015 26
Figure 20: Gemzar, NSCLC, Spain, Sales Forecast ($m), 2002-2015 27
Figure 21: Gemzar, NSCLC, Japan, Sales Forecast ($m), 2002-2015 28
Figure 22: GlobalData Methodology 29
Figure 23: Drug Model Diagram 31
Figure 24: Patients Approved for the Drug 31

Make an enquiry before buying this Report

Please fill the enquiry form below.

  • Full Name *
  • Your Email *
  • Job Title *
  • Company *
  • Phone No. * (Pls. Affix Country Code)
  • Message
  • Security Code *